



TRACON to Report First Quarter 2015 Company Highlights and Financial Results on May 13, 2015

San Diego, CA – May 6, 2015 – TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, announced today that it will report its first quarter 2015 financial and operating results after the close of U.S. financial markets on Wednesday, May 13, 2015. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

Conference call and webcast:

Date: May 13, 2015

Time: 4:30 pm Eastern Daylight Time (1:30 pm Pacific Daylight Time)

Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)

Passcode: 42021957

Via web: www.traconpharma.com; "Events and Presentation" section within the "Investors" section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Contact:

Casey Logan

Chief Business Officer

(858) 550-0780 ext. 236

clogan@traconpharma.com